Molecular Trends in Glaucoma Therapy

MarinBio Blog

Aqueous humor buildup in glaucoma creates pressure that damages the optic nerve.[/caption]

Molecular Trends in Glaucoma Therapy

Glaucoma represents a group of progressive optic neuropathies characterized by the degeneration of retinal ganglion cells and corresponding visual field loss. It is a leading cause of irreversible blindness worldwide, affecting millions of individuals across diverse populations. Clinically, glaucoma encompasses a spectrum of disease presentations, from open-angle to angle-closure subtypes, and varies in its etiology, rate of progression, and response to treatment. Although elevated intraocular pressure (IOP) is a major risk factor, glaucoma can also develop in individuals with “normal” IOP, highlighting the complex and multifactorial nature of this condition. Continued advances in diagnostic technology, molecular biology, and therapeutic innovation are reshaping our understanding of glaucoma pathogenesis and management.

What is Glaucoma?

Glaucoma is a neurodegenerative ocular disease primarily defined by the progressive loss of retinal ganglion cells (RGCs), accompanied by characteristic structural changes to the optic nerve head and associated visual field deficits. RGCs are neurons in the retina that receive visual information from photoreceptors through intermediate cells (bipolar and amacrine cells) and transmit it to the brain via their axons, which form the optic nerve. Essentially, they act as the eye’s output neurons, converting visual signals into electrical impulses for processing in the brain. The condition is heterogenous, with primary open-angle glaucoma and primary angle-closure glaucoma representing the two major clinical forms. Secondary glaucomas arise due to identifiable causes such as trauma, inflammation, steroid response, or vascular disorders. Regardless of subtype, the common end point is optic nerve damage, which if left untreated, culminates in irreversible vision loss.

The Pathophysiology of Glaucoma

Glaucoma develops through several interacting processes that ultimately damage retinal ganglion cells and the optic nerve. High eye pressure is a major factor and places physical stress on the optic nerve, especially at the lamina cribrosa, a sieve-like connective tissue structure in the optic nerve head through which retinal ganglion cell axons exit the eye. This stress interferes with normal transport inside nerve fibers. Over time, stress weakens the optic nerve head leading to degeneration and loss of retinal ganglion cells. The weakened structure also makes the optic nerve more sensitive to pressure fluctuations and reduced blood flow, further increasing injury.

Reduced or unstable blood flow to the eye plays a role by limiting oxygen and nutrient supply and making nerve cells more vulnerable to injury. Other harmful processes, including oxidative stress, poor mitochondrial function, excessive excitatory signaling, and inflammation, further disrupt normal cell function. Clinically, these changes translate into thinning of the retinal nerve fiber layer, progressive visual field defects, and ultimately irreversible vision loss if the disease is not controlled.

Cellular and Molecular Mechanisms of Glaucoma Development

At the cellular level, glaucoma involves the following:

• Retinal ganglion cell apoptosis,
• Axonal degeneration,
• Remodeling of extracellular matrix within the optic nerve head and trabecular meshwork.
• Elevated IOP and associated mechanical stress
• Activation of signaling pathways in RGCs, astrocytes, and lamina cribrosa cells

Key molecular mediators include:

• Calcium influx,
• Caspase activation
• Activation of pro-apoptotic factors
• Oxidative stress leading to DNA damage and mitochondrial dysfunction
• Release of cytokines and chemokines that sustain neuroinflammation.
• Dysregulated neurotrophic support
• Changes in matrix metalloproteinase activity leading to elevated outflow resistance

Disease Progression

The progression of glaucoma is a continuum from preclinical risk to advanced vision loss. Initially, individuals may exhibit elevated intraocular pressure without detectable optic nerve or field changes, a state termed ocular hypertension. As disease progresses, structural changes in the optic nerve head, such as increased cupping and retinal nerve fiber layer thinning, emerge. Concurrently, functional deficits appear on visual field testing, often first in the peripheral field before encroaching centrally. With continued insult, RGC apoptosis accelerates, visual field defects deepen and enlarge, and optic nerve damage advances. In later stages, significant loss of RGCs leads to constricted visual fields, decreased contrast sensitivity, and eventual central vision compromise. Without intervention, bilateral blindness can occur. The rate of progression varies widely among individuals, influenced by factors such as baseline IOP, age, vascular health, and treatment adherence.

Current Therapies

Current therapies for glaucoma aim to lower intraocular pressure, the only modifiable risk factor proven to slow disease progression. Medical management includes topical pharmacologic agents such as prostaglandin analogs, beta-adrenergic blockers, alpha-adrenergic agonists, carbonic anhydrase inhibitors, and rho kinase inhibitors. These medications reduce aqueous humor production or enhance outflow through trabecular and uveoscleral pathways. Laser therapies, such as selective laser trabeculoplasty (SLT) and argon laser trabeculoplasty (ALT), enhance trabecular outflow and are increasingly used as first-line or adjunctive treatments. Surgical interventions, including trabeculectomy, glaucoma drainage implants, and minimally invasive glaucoma surgeries (MIGS), provide more sustained IOP reduction when medical or laser therapy is insufficient. These procedures create alternative outflow pathways or modify existing structures to reduce resistance.

Limitations of Current Therapies

Despite advances in treatment, current therapies have significant limitations. Many pharmacologic agents are associated with local and systemic side effects, including ocular surface irritation, hyperemia, systemic cardiovascular effects, and patient intolerance, which can compromise adherence. Topical treatments require consistent daily administration, and nonadherence remains a major barrier to effective IOP control. Laser therapies may lose efficacy over time and are not universally effective. Surgical interventions, while potent, carry risks such as hypotony, infection, fibrosis, and bleb failure, and their long-term success is variable. Importantly, IOP-lowering therapies do not directly address underlying neurodegenerative mechanisms and therefore may not fully halt retinal ganglion cell loss in all patients, especially those with normal-tension glaucoma. There remains an unmet need for neuroprotective and disease-modifying treatments that preserve neuronal integrity independent of IOP.

Investigational Drug Targets for Glaucoma

Glaucoma is a complex neurodegenerative disease characterized by progressive retinal ganglion cell (RGC) loss and optic nerve damage, often associated with elevated intraocular pressure (IOP). Glaucoma drug discovery increasingly integrates human genetics, molecular biology, and pharmacology. While traditional therapies primarily focus on lowering IOP, a growing body of research highlights additional mechanisms that contribute to disease progression, including extracellular matrix (ECM) remodeling, oxidative stress, dysregulated signaling pathways, and impaired neuroprotection.

In vivo non-human models are essential for studying glaucoma pathophysiology and evaluating therapeutic strategies, as they enable controlled manipulation of intraocular pressure (IOP), optic nerve damage, and retinal ganglion cell degeneration in a physiological context. Commonly used models include rodent models (mouse and rat), where glaucoma is induced by methods such as microbead occlusion or laser photocoagulation to study genetic risk factors and neurodegeneration; a few examples are Microbead occlusion models in mice or rats involve injection of polystyrene or magnetic microbeads into the anterior chamber to block aqueous humor outflow, producing a sustained elevation in intraocular pressure (IOP) and progressive retinal ganglion cell (RGC) loss. Laser-induced ocular hypertension models use laser photocoagulation of the trabecular meshwork or episcleral veins to impair drainage, enabling precise temporal control of IOP elevation and reproducible optic nerve damage. Genetic mouse models, such as DBA/2J mice, develop age-dependent increases in IOP due to iris pigment dispersion and mimic chronic glaucoma progression, making them useful for studying disease genetics and long-term neurodegeneration.

The following list summarizes several promising molecular targets currently under investigation for glaucoma therapeutics. Each target is presented with its molecular and cellular function, physiological relevance, role in glaucoma pathology, drug modality, mechanism of therapeutic action, and stage of drug development. These targets span a spectrum from well-validated pathways with approved drugs, to emerging, genetically nominated candidates that are primarily in the discovery or preclinical phase. By highlighting both the mechanistic rationale and development stage, the list provides a comprehensive overview of the evolving landscape of glaucoma drug discovery.

Thioredoxin‑interacting protein (TXNIP)

• Role: Drives oxidative stress and inflammatory microglial activation, promoting RGC loss via PI3K/Akt pathways
• Evidence: TXNIP knockout or inhibition promotes RGC survival and reduces inflammation in chronic ocular hypertension mouse models (in vivo)
• Development stage: Preclinical; small molecule inhibitors and gene knockdown approaches being explored for neuroprotective intervention.

Receptor‑interacting protein kinase 1 (RIP1/RIPK1)

• Role: Promotes necroptotic and inflammatory signaling contributing to RGC degeneration
• Evidence: RIP1 catalytically‑dead mice show preserved RGC survival and retinal function after optic nerve crush and ischemia–reperfusion injury (in vivo)
• Development stage: Preclinical; kinase inhibitors being evaluated for neuroprotection.

Brain‑derived neurotrophic factor (BDNF)/TrkB receptor

• Role: Provides neurotrophic support signaling that prevents RGC apoptosis
• Evidence: AAV‑mediated delivery of BDNF/TrkB enhances RGC survival and axonal integrity in experimental glaucoma in vivo
• Development stage: Preclinical to early translational; gene therapy constructs (AAV) and recombinant proteins.

Nicotinamide mononucleotide adenylyltransferase 1 (Nmnat1)

• Role: Enhances NAD+ synthesis, helping mitigate mitochondrial dysfunction in RGCs
• Evidence: Gene therapy increasing Nmnat1 expression protects RGCs in mouse glaucoma models (in vivo)
• Development stage: Preclinical; viral gene therapy vectors.

Aquaporin‑1 (AQP1)

• Role: Water channel in ciliary body increases intraocular pressure and secondary RGC loss
• Evidence: CRISPR‑mediated Aqp1 disruption in mice lowers IOP and prevents RGC loss in glaucoma models (in vivo)
• Development stage: Preclinical/Translational; gene editing (CRISPR‑Cas systems) and RNA editing (Cas13) strategies.

Matrix metalloproteinase‑1 (MMP1)

• Role: ECM remodeling increases aqueous humor outflow. In glaucoma, the trabecular meshwork’s extracellular matrix (ECM) can become dense or stiff, increasing resistance to aqueous humor outflow and raising intraocular pressure. This increased outflow helps lower intraocular pressure, which is key to protecting the optic nerve and slowing glaucoma progression.
• Evidence: MMP1 expression decreases ECM deposition and improves outflow in steroid‑induced glaucoma models (in vivo)
• Development stage: Preclinical; gene therapy to enhance MMP expression.

Microglial TNF‑α signaling

• Role: Pro‑inflammatory cytokine drives RGC apoptosis and neuroinflammation
• Evidence: TNF‑α antagonists reduce microglial activation and RGC loss in ocular hypertension models (in vivo)
• Development stage & modalities: Preclinical; biologic inhibitors and small molecule antagonists.

Sigma‑1 receptor (σ‑1R)

• Role: Modulates calcium homeostasis and mitochondrial stress signaling to support RGC survival
• Evidence: Sigma‑1 agonists protect RGCs in experimental glaucoma models (in vivo)
• Development stage & modalities: Preclinical; small molecule agonists (e.g., sigma‑1 modulators) being tested for neuroprotection.

Glaucoma drug discovery continues to evolve beyond intraocular pressure-lowering strategies to target neuroprotection, ECM regulation, oxidative stress, and metabolic resilience. Progressing these targets through robust preclinical validation and translational clinical development will be essential for expanding therapeutic options that slow neurodegeneration and preserve vision, in addition to controlling intraocular pressure.

Drug Modalities in Development

The table below presents an overview of drug modalities under development for the treatment of glaucoma, highlighting a shift beyond conventional intraocular pressure (IOP)–lowering eye drops toward a broader range of therapeutic strategies. These include small molecules, biologics, gene and gene-editing therapies, nanoparticle-based delivery systems, and stem cell–based approaches. For each modality, the table summarizes representative investigational therapies, their target cells and molecular targets, the biological processes they influence, and their proposed mechanisms of action. Together, these emerging strategies reflect a growing recognition of glaucoma as a complex neurodegenerative disease, with therapies designed not only to improve aqueous humor dynamics and reduce IOP, but also to provide neuroprotection, limit fibrosis, and support tissue repair or regeneration. Although many of these approaches are still in preclinical or early translational stages, their diversity points toward future combination and disease-modifying treatments aimed at better preserving vision and slowing or halting glaucoma progression.

Table 1.  Representative drug modalities in development for Glaucoma therapy.

Clinical Trials

Clinical development in glaucoma has expanded well beyond traditional intraocular pressure (IOP)–lowering eye drops and now reflects a diverse set of biological and molecular approaches. These efforts signal a gradual shift from symptomatic control toward longer-acting and potentially disease-modifying interventions. Examples of glaucoma clinical trials using different therapeutic modalities are shown below, and include small molecules, monoclonal antibodies, recombinant protein and AAV based gene therapy.

Small Molecules

One advanced small-molecule program is a nitric oxide–donating prostaglandin analog that has progressed through Phase 2 and into Phase 3 clinical development. By combining prostaglandin  with nitric oxide, the drug is designed to produce greater and more sustained IOP lowering than conventional prostaglandin analogs alone. Clinical trial data to date suggest enhanced efficacy with an acceptable safety profile, positioning it as an incremental but clinically meaningful advance within the late-stage development landscape.

Monoclonal Antibodies

Among antibody-based approaches, ANGPTL7-targeting monoclonal antibodies represent a novel strategy aimed at the extracellular matrix are currently in early-to-mid clinical development, including Phase 1/2 studies. ANGPTL7 is implicated in outflow resistance and has genetic and experimental links to glaucoma risk. Antibody inhibition of ANGPTL7 in these trials seeks to normalize extracellular matrix composition and improve conventional outflow, offering a mechanistically distinct alternative to prostaglandin signaling and illustrating how human genetics is beginning to inform biologic drug design in glaucoma.

Protein Therapeutics

Protein therapeutics are exemplified by recombinant human nerve growth factor (rhNGF; cenegermin), which has advanced into early clinical evaluation for glaucomatous neuroprotection. In glaucoma, rhNGF is being assessed primarily in Phase 1/2 clinical studies focused on safety, dosing, and exploratory efficacy. Unlike pressure-lowering drugs, rhNGF is intended to support retinal ganglion cell survival and optic nerve health by activating pro-survival signaling pathways, reflecting a shift toward direct neuroprotective strategies in clinical testing.

Gene Therapy

A more transformative modality is represented by AAV-based gene therapies, several of which have entered first-in-human Phase 1/2 clinical trials for glaucoma. These programs use AAV vectors to deliver genes that remodel extracellular matrix or enhance aqueous outflow, with the goal of achieving long-term IOP reduction after a single administration. By aiming for durable changes in outflow physiology, these trials seek to reduce or eliminate the need for daily eye drops, addressing adherence challenges while testing the feasibility of one-time or infrequent treatments.

Overall, advanced glaucoma trials now encompass a broad spectrum of modalities and stages of development, from early safety-focused gene and protein therapies to late-stage small molecules nearing potential approval. While most late-phase programs remain centered on IOP lowering, an important subset of earlier-stage trials is exploring neuroprotection and long-lasting tissue modification, signaling movement toward disease-modifying concepts. Although a true cure remains elusive, the diversity of approaches progressing through clinical development suggests that future glaucoma management may integrate durable pressure control with direct protection of the optic nerve, fundamentally reshaping therapeutic strategies.

Conclusion

Glaucoma remains a leading cause of irreversible vision loss worldwide, driven by complex interactions among mechanical, vascular, cellular, and molecular processes. While current therapies that lower intraocular pressure have significantly improved outcomes, they are limited by side effects, adherence challenges, and an incomplete ability to stop neurodegeneration. Advances in our understanding of the pathophysiology of glaucoma are guiding the development of innovative diagnostic tools and novel therapies that pursue neuroprotection, regeneration, and targeted molecular modulation. Continued research is critical to translate these scientific insights into effective clinical interventions that preserve vision and quality of life for individuals with glaucoma.